

OMB#: 0925-0648, Exp., 06/2024

Burden Disclosure Statement: Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648) Do not return the completed form to this address.

1. Is this your first time participating in a review meeting for NIH (not including service as a mail reviewer)?

* No
* Yes
* Don't know

2. Was your review meeting held virtually, face-to-face or in a hybrid format? **Please read all response options carefully before selecting.**

* Virtually--all reviewers met virtually via Zoom with audio and video capabilities
* Face-to-face
* Face-to face but I attended virtually via Zoom with audio only
* Hybrid--approx. half of reviewers met face-to-face and half joined virtually via Zoom with audio and video capabilities

3. If you participated in a hybrid meeting, did you attend the meeting virtually or face-to-face?

* Virtually
* Face-to-face
* I did not attend a hybrid meeting

4. If you participated in a hybrid meeting or if you participate in a hybrid meeting in the future, how would you prefer (or have preferred) to attend?

* Virtually
* Face-to-face
* No preference

5. Please select how much you agree or disagree with the following statements.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Strongly agree | Agree | Somewhat agree | Neutral | Somewhat disagree | Disagree | Strongly disagree |
| The panel was able to prioritize applications according to their impact and scientific merit. |  |  |  |  |  |  |  |
| The scientific discussion helped the panel evaluate the applications being reviewed. |  |  |  |  |  |  |  |

6. Please rate your recent review meeting on the following items.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Excellent | Good | Fair | Poor | Very poor | Don't know/Not applicable |
| Overall quality of review |  |  |  |  |  |  |
| Productivity of discussions |  |  |  |  |  |  |
| Level of reviewer engagement |  |  |  |  |  |  |
| Meeting management |  |  |  |  |  |  |

7. Please rate your recent review meeting on the following items.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Always or very frequently | Often | Sometimes | Rarely | Never | Don't know/Not applicable |
| I contributed to the discussion. |  |  |  |  |  |  |
| I felt confident voicing my opinions. |  |  |  |  |  |  |
| I felt others were receptive and responsive to my feedback. |  |  |  |  |  |  |
| I was able to clearly communicate my opinions. |  |  |  |  |  |  |
| I felt comfortable voting outside the range. |  |  |  |  |  |  |

8. Rate your attention span at the review meeting from 1-10, with 1 being really struggled to concentrate and 10 being no problem concentrating at all.



|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |

9. Assuming no or minimal health risks from COVID-19, would you be more likely to participate in a review meeting if it was held face-to-face or over video/Zoom?

* Face-to-face
* Video/Zoom
* No preference

10. Did you experience any technical difficulties with your review meeting (e.g. audio, visual, connecting)?

* Yes
* No
* Don't know

11. Approximately how many review meetings have you participated in for NIH?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | 0 | 1 | 2-5 | 6-15 | 16+ |
| Face-to-face meetings |  |  |  |  |  |
| Virtual meetings |  |  |  |  |  |

12. What stage of your career are you in?

* Assistant Professor
* Associate Professor
* Professor
* Other

13. What is your sex?

* Male
* Female
* I prefer not to respond

14. Are you Hispanic or Latino?

* Yes
* No
* I prefer not to respond

15. Which racial group(s) do you primarily identify as? Select all that apply.

* American Indian or Alaska Native
* Asian
* Black or African-American
* Native Hawaiian or other Pacific Islander
* White
* I prefer not to respond

16. In which U.S. time zone do you live?

* Eastern Time (ET)
* Central Time (CT)
* Mountain Time (MT)
* Pacific Time (PT)
* Alaska Time (AT)
* Hawaii-Aleutian Time (HAT)
* Other U.S. time zone
* I do not live in a U.S. time zone

17. Please share any comments (positive or negative) about your experience or general thoughts on your recent review meeting.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_